3-Month Landmark Analysis of OS
CheckMate 057: Nivolumab vs Docetaxel in Previously Treated NSQ NSCLC
Nivo
(n = 232)
Doc
(n = 244)
Median OS, mo
17.4
11.3
Events, n
131
179
HR (95% CI)
0.59 (0.47, 0.74)
Alive at 3 Months −
All Patients
ITT Population
1
Nivo
(n = 292)
Doc
(n = 290)
Median OS, mo
12.2
9.4
Events, n
190
223
HR (96% CI)
0.73 (0.59, 0.89)
Months
100
90
80
70
60
50
40
30
10
0
20
27
21
18
15
12
9
6
3
0
24
Nivo
(n = 82)
Doc
(n = 87)
Median OS, mo
14.7
11.4
Events, n
51
62
HR (95% CI)
0.66 (0.45, 0.97)
Alive at 3 Months –
Patients With <1% PD-L1 Expression
Months
100
90
80
70
60
50
40
30
10
0
20
27
21
18
15
12
9
6
3
0
24
OS (%)
Months
100
90
80
70
60
50
40
30
10
0
20
27
21
18
15
12
9
6
3
0
24
Nivolumab
Docetaxel
Peters S, et al. WCLC 2016
